In the adjuvant setting, the KATHERINE trial established T-DM1 as the standard of care for patients with HER2-positive early breast cancer who had residual invasive disease after completion of neoadjuvant standard treatments. This evidence concerns the gene ERBB2 and breast carcinoma.